- Home
- IMTX vs EOLS Comparison
IMTX vs EOLS Comparison
Compare IMTX & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- EOLS
- Stock Information
- Founded
- IMTX N/A
- EOLS 2012
- Country
- IMTX Germany
- EOLS United States
- Employees
- IMTX N/A
- EOLS N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- IMTX Health Care
- EOLS Health Care
- Exchange
- IMTX Nasdaq
- EOLS Nasdaq
- Market Cap
- IMTX 653.9M
- EOLS 589.3M
- IPO Year
- IMTX N/A
- EOLS 2018
- Fundamental
- Price
- IMTX $6.56
- EOLS $9.53
- Analyst Decision
- IMTX Strong Buy
- EOLS Strong Buy
- Analyst Count
- IMTX 4
- EOLS 5
- Target Price
- IMTX $14.67
- EOLS $23.75
- AVG Volume (30 Days)
- IMTX 405.6K
- EOLS 889.3K
- Earning Date
- IMTX 08-12-2025
- EOLS 08-05-2025
- Dividend Yield
- IMTX N/A
- EOLS N/A
- EPS Growth
- IMTX N/A
- EOLS N/A
- EPS
- IMTX N/A
- EOLS N/A
- Revenue
- IMTX $155,801,989.00
- EOLS $275,463,000.00
- Revenue This Year
- IMTX N/A
- EOLS $33.42
- Revenue Next Year
- IMTX $1.92
- EOLS $33.18
- P/E Ratio
- IMTX N/A
- EOLS N/A
- Revenue Growth
- IMTX 93.56
- EOLS 25.38
- 52 Week Low
- IMTX $3.30
- EOLS $8.67
- 52 Week High
- IMTX $13.09
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- IMTX 66.69
- EOLS 51.00
- Support Level
- IMTX $5.70
- EOLS $9.12
- Resistance Level
- IMTX $6.57
- EOLS $10.20
- Average True Range (ATR)
- IMTX 0.33
- EOLS 0.40
- MACD
- IMTX 0.05
- EOLS 0.05
- Stochastic Oscillator
- IMTX 99.50
- EOLS 44.17
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.